Ann: Proteomics International seeks FDA approval for PromarkerD, page-176

First 176 Last

Share
Profile

Follow
Owl vs Fox

6,434 Posts.

5274

24/02/21

17:04

Post #: 51292506
Share

Originally posted by pezzstocks: ↑

Seems like a few healthcare stocks going on a move of late and the market finally waking up to how undervalued PIQ is compared to peers.

RHY - mkt cap ~$140m, large potential market but still a few years away (1-2 years?) from test hitting the mkt, no pipeline mentioned in AGM Preso.

RENX/RNLX - mkt cap ~A$700m, smaller target market than PIQ (going after late stage DKD), no commercial sales, no CE Mark, no pipeline mentioned in company presos.

PIQ - mkt cap $58m - large target market, test is CE Mark approved, initial licence deals executed, first sales in in CY21, broad/deep pipeline of other diagnostic tests.

Plus other mkt caps in peer group table below:

If PIQ has a market cap of $140m, like RHY, share price will be $1.33

If PIQ has a market cap of the ave of some of its peers below, say $250m, share price will be $2.38

I'll leave everyone to do their own calcs for what the SP would be if they get to RENX's mkt cap....

------------------------------------------------------------

This is a quoted post from@Tulip2000

This is spot on, this was before the announcement of an FDA application. IMO it's not unreasonable for a fair valuation of $250-300M ($2.5-$3) market cap right now. And if the FDA approval comes through, this is a willy wonka golden ticket and should come with a re-rating, it's not unreasonable to expect a $500-600M market cap, or about $6-7 per share. Then, it would be a matter of the up take and commercial rollout/update, in which there is infinite upside. And this is just for PromarkerD. We still have so much other R & D in the pipeline. My favorite is the endo test. A endometriosis test would be a game changer, currently there is no known test other than invasive surgery. All IMO. GLTAH.

Expand

100% agree with you Pezz & @snowunda will thank you guys today for helping with the maths homework lol.

Things have even changed since this investor info @Tulip2000, posted eg:

RHY ASX: MC A$292.8M - SP $1.45
RNLX: MC US$828.34M (>A$1B) - SP US$23.00 (& has slid a bit lately.

Some really good analysis there in your post & I think it makes a lot of sense on your valuation when taking into consideration where PIQ are at with PromarkerD in progress both with the test & regulatory approvals, both done & pending (FDA).

Thanks Pezz

PIQ Price at posting: $1.25 Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

SNG

Siren Gold boosts antimony resource by 66% to 14.5Kt at Auld Creek, NZ

WR1

Winsome scoping study proposes low-cost operation for Adina lithium project

WMG

Western Mines identifies 2 high-grade zones at Mulga Tank in WA

PTR

Petratherm adds $1.6 to the piggybank ahead of SA titanium drilling program

ALR

Altair Minerals hits high-grade copper and gold at Wee MacGregor, QLD